FDA Approves Johnson & Johnson's Icotyde for Moderate-to-Severe Plaque Psoriasis
The U.S. Food and Drug Administration has approved Johnson & Johnson's Icotyde (icotrokinra), an interleukin-23 (IL-23) receptor antagonist, for the treatment of moderate-to-severe plaque psoriasis in adults.
·1 source
